SEATTLE, Sept. 18 /PRNewswire-FirstCall/ -- Omeros Corporation today announced the launch of its initial public offering of 6.82 million shares of its common stock. Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system.
The estimated price range for the initial public offering is $10.00 to $12.00 per share. Omeros has applied to have the shares of common stock listed on The NASDAQ Global Market under the ticker symbol "OMER." The underwriters have the option to purchase up to an additional 1.02 million shares to cover over-allotments, if any. All of the shares of common stock will be offered by Omeros.
Omeros intends to use the net proceeds of the offering to fund the completion of its Phase 3 clinical trials of OMS103HP, its lead product candidate being evaluated for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain, as well as the potential launch and commercialization of OMS103HP. The Company also intends to use the net proceeds to fund the development of its other product candidates in the clinic, OMS302 for ophthalmology and OMS201 for urology, and the development of its pipeline of preclinical programs.
Deutsche Bank Securities Inc. will be acting as the sole book-running manager. Wedbush PacGrow Life Sciences will be acting as the co-lead manager, Canaccord Adams Inc. and Needham & Company, LLC will be acting as co-managers, and Chicago Investment Group, LLC and National Securities Corporation will be acting as junior co-managers. The offering will be made only by means of a prospectus.
Copies of the preliminary prospectus may be obtained by contacting: Deutsche Bank Securities Inc. by mail, Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, by telepho
|SOURCE Omeros Corporation|
Copyright©2009 PR Newswire.
All rights reserved